Product Information
Registration Status: ActiveSIN06923P
CARBIMAZOLE 5 TABLET 5mg is approved to be sold in Singapore with effective from 1992-03-23. It is marketed by GOLDPLUS UNIVERSAL PTE LTD, with the registration number of SIN06923P.
This product contains Carbimazole 5mg in the form of TABLET, FILM-COATED. It is approved for ORAL use.
This product is manufactured by REMEDICA LTD in CYPRUS.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
An imidazole antithyroid agent. Carbimazole is metabolized to methimazole, which is responsible for the antithyroid activity.
Indication
For the treatment of hyperthyroidism and thyrotoxicosis. It is also used to prepare patients for thyroidectomy.
Mechanism of Action
Carbimazole is an aitithyroid agent that decreases the uptake and concentration of inorganic iodine by thyroid, it also reduces the formation of di-iodotyrosine and thyroxine. Once converted to its active form of methimazole, it prevents the thyroid peroxidase enzyme from coupling and iodinating the tyrosine residues on thyroglobulin, hence reducing the production of the thyroid hormones T3 and T4.
Active Ingredient/Synonyms
1H-Imidazole-1-carboxylic acid, 2,3-dihydro-3-methyl-2-thioxo-, ethyl ester Ethyl 3-methyl-2-thioimidazoline-1-carboxylate | Athyromazole | Carbethoxymethimazole | Carbimazol | Carbimazolo | Carbimazolum | Carbinazole | Ethyl 3-methyl-2-thioimidazoline-1-carboxylate | Carbimazole |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.